Theranostics
, CD80/86→ CTLA-4; PD-L1/L2→PD-1), activated CTLA-4 and PD-1 immune checkpoint signaling pathways efficiently inhibit the tumor-reactive T cell activation and consequent tumor detection[42]. A phase II clinical trial of individual drug Nivolumab and also a combination of dual drugs like Nivolumab plus Ipilimumab is in undergoing process for ... ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.